Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation
Study Details
Study Description
Brief Summary
The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who experienced ASR.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
LN patients who presented with ASR [defined as 1) increase in anti-dsDNA >100 IU/mL , with or without drop in serum complement; or 2) increase in anti-dsDNA to higher than the normal range and >2 times of the preceding value, with or without drop in serum complement; and 3) Absence of renal or systemic manifestations of SLE) will be randomized to receive pre-emptive increase in immunosuppression or had their current immunosuppressive therapies unchanged.
Patients will be followed at 4-, 12-, 24-wk and then every 12 weeks up to 24 months to monitor for renal or extra-renal relapses. Bloods and urine will be collected for measurement of renal and serological parameters, and also B cell signatures.
Primary outcomes: Renal Flare (denoted as proteinuria >1g/D; presence of urinary RBC >30 hpf/RBC casts, or increase in SCr >15% and positive anti-dsDNA)
Secondary outcomes:
-
Safety & tolerability of pre-emptive increase of immunosuppressive treatments
-
Extra-renal flares
-
Renal function at 24 months
-
Changes in serological parameters
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Pre-emptive Treatment (Prednisolone and/or AZA/MMF) Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks. Adjustment of the 2nd agent would be as follows: For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day. For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day. |
Procedure: Pre-emptive increase of immunosuppressive treatments
Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.
Adjustment of the 2nd agent would be as follows:
For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.
For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day.
Drug: Prednisolone and/or AZA/MMF
Prednisolone and/or AZA/MMF
|
| No Intervention: Control Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression. |
Outcome Measures
Primary Outcome Measures
- Renal Flare [Within 24 months]
A composite endpoint denoted by proteinuria >1g/day, presence of urinary RBC >30/hpf or RBC casts, or increase in serum creatinine by 15% compared with baseline, and anti-DNA antibody titre above the upper limit of normal
Secondary Outcome Measures
- Infections requiring hospitalization [24 months]
- Extra-renal flares [24 months]
- Serum creatinine levels [24 months]
- Changes in anti-dsDNA [24 months]
- Changes in C3 [24 months]
- Changes in Hba1c [24 months]
- Changes in fasting glucose [24 months]
- Changes in LDL levels [24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with biopsy-proven lupus nephritis who experienced an episode of Asymptomatic
Serological Flare (ASF) as defined by:
-
Increase in anti-dsDNA to >100 IU/mL, with or without drop in serum complement levels OR
-
Increase in anti-dsDNA to higher than the normal range and more than two times of the preceding value, with or without drop in serum complement levels
AND
- Absence of renal or systemic manifestation of SLE.
Exclusion Criteria:
-
Patients who cannot provide informed consent.
-
Patients whom the clinicians opined to have excessively high risk of infection or malignancy.
-
Patients who are pregnant or lactating.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Queen Mary Hospital, Hong Kong | Hong Kong | Hong Kong | ||
| 2 | United Christian Hospital | Hong Kong | Hong Kong |
Sponsors and Collaborators
- The University of Hong Kong
- United Christian Hospital
Investigators
- Principal Investigator: Desmond YH Yap, MBBS (HK). MD (HK), Queen Mary Hospital, The University of Hong Kong
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UW-16-074